Transthyretin– tag –
-
Hereditary Transthyretin Amyloidosis Market: Intellia/Regeneron’s CRISPR Gene Editor Nexiguran ziclumeran Receives FDA RMAT Designation
GlobeNewswire USA Overview This article summarizes a market research report by DelveInsight on the hereditary transthyretin amyloidosis (hATTR) market. The report highlights Nexiguran ziclumeran (nex-z), a CRISPR-Cas9-based gene-editing ... -
FDA Lifts Clinical Hold on Intellia Therapeutics’ Phase 3 Trial for nex-z in Transthyretin Amyloidosis
Intellia Therapeutics (via LinkedIn) USA Overview Intellia Therapeutics announced the FDA has lifted the clinical hold on its Phase 3 MAGNITUDE-2 clinical trial for nexiguran ziclumeran (nex-z), a therapeutic candidate for transthyretin ... -
Intellia Therapeutics Advances CRISPR Gene Editing: Lonvo-z Achieves Phase 3 Success for HAE, Targeting Mid-2027 U.S. Launch; Nex-z Phase 3 Enrollment Resumes for ATTR
Intellia Therapeutics, Inc. (Press Release) USA Overview Intellia Therapeutics reported positive Phase 3 results for lonvo-z in hereditary angioedema (HAE), with a Biologics License Application (BLA) submission to the FDA planned for H2 ... -
Intellia Therapeutics Sees Steady Progress with HAE Therapy Lonvo-Z and ATTR Amyloidosis Therapy Nex-Z; FDA Lifts Clinical Hold on Nex-Z
Seeking Alpha USA Overview Intellia Therapeutics has demonstrated steady progress in the clinical development of Lonvo-Z for hereditary angioedema (HAE) and Nex-Z for ATTR amyloidosis. Positive data reported from the Phase 3 HAELO study ...
1